BlueWind Medical Raises $64M in Series B Funding

BluWind Medical, Park City, UT – and Herzliya, Israel-based developer of the RENOVA iStim implantable tibial neuromodulation device, raised $64M in Series B funding.

TheConvaTec led round.

TheCompany plans to use the funds in order to expand its commercial presence in anticipation of potential FDA marketing clearance for its RENOVA iStim implantable neuromodulation device.

LedBy CEO Dan LemaitreBluWind Medical develops the innovative RENOVA iStim implantable tibial neuromodulation device, which is under investigation for the treatment of urgency incontinence alone or incombination with urgency and/or frequency of urinary problems. RENOVA iStim is implanted near the ankle inLocal anesthesia is used for a short, outpatient procedure lasting approximately 30 minutes. 



Leave a Comment